Pharmaceutical Sales: 100% (2025)

TOP 3 Markets:

1. China: approx. 70%
2. USA: approx. 20%
3. Europe: approx. 10%

RemeGen Co., Ltd. is a biopharmaceutical company specializing in the research, development, and marketing of innovative drugs. The majority of sales come from the pharmaceutical industry, particularly from the sale of drugs for the treatment of cancer and autoimmune diseases.

China remains the main market for RemeGen, attributed to its strong local presence and the growing demand for innovative therapies. The U.S. market is also significant as the company has intensified its international expansion efforts there. Europe represents the third important market where RemeGen is increasingly establishing its products.

Production Sites: Yantai, China

RemeGen Co., Ltd. mainly produces its biopharmaceutical products in Yantai, China. The company has established modern production facilities there to manufacture its innovative medicines, especially in the field of antibody therapies. This strategic location choice enables RemeGen to benefit from the proximity to important research and development centers as well as efficient logistics within China.

Focus on Research and Development: RemeGen invests heavily in R&D to develop innovative biopharmaceutical products.

International Expansion: The company plans to expand its presence in global markets, especially in the USA and Europe.

Partnerships and Collaborations: RemeGen aims to form strategic alliances with other pharmaceutical companies to accelerate the market introduction of new products.

RemeGen Co., Ltd. pursues a growth strategy that heavily emphasizes innovation and international expansion. Through significant investments in research and development, the company aims to expand its pipeline of biopharmaceutical products. There is a particular focus on oncology and autoimmune diseases.

Additionally, RemeGen plans to strengthen its presence in international markets to capitalize on the increasing demand for innovative therapies. Partnerships and strategic alliances with other companies are also a key component of the growth strategy to leverage synergies and accelerate the market introduction of new products.

Main raw materials: Biopharmaceutical active ingredients, laboratory chemicals
Main importing countries: USA, Germany, Switzerland

RemeGen Co., Ltd., a biopharmaceutical company, mainly imports biopharmaceutical active ingredients and special laboratory chemicals needed for the research and development of new drugs.

The USA is a significant supplier of innovative biotechnological materials and technologies. Germany and Switzerland are known for their high-quality pharmaceutical products and chemicals that are crucial for RemeGen's biopharmaceutical research.

These imports are crucial for maintaining the high standards in research and development that RemeGen pursues to remain competitive in the global market.

Market Share in Biotechnology: Estimated 5-7% (2025)

R&D Investments: 20% of revenue (2024)

RemeGen Co., Ltd. has gained a significant competitive advantage through its strong investments in research and development. With approximately 20% of revenue allocated to R&D, the company positions itself as an innovative player in the field of biotechnology.

Another advantage is the specialization in antibody and fusion protein therapies, which are considered groundbreaking in the industry. Through strategic partnerships and a robust pipeline of clinical studies, RemeGen can further enhance its market position.

The competitive advantage is also reinforced by intellectual property protection and the ability to bring new products to market faster than many competitors. This enables the company to successfully navigate a dynamic and highly competitive market environment.

Institutional Investor Share: Approximately 45% (estimated for 2025 based on trends)

Insider Buys/Sells: No significant transactions in the last year (2024)

The institutional investor share in RemeGen Co., Ltd. is estimated to be around 45%. This reflects the confidence of institutional investors in the company, especially in a volatile market environment.

In 2024, there were no significant insider buys or sells, indicating a stable internal assessment of the company's development. Insider activities are often seen as an indicator of the company's future performance, and the absence of such transactions suggests a consistent trust of the management in the current company strategy.

Market share of RemeGen Co., Ltd.: Estimate 3-5% (2025)

Top competitors and their market share:

1. Roche Holding AG: approx. 15%
2. Novartis AG: approx. 12%
3. Pfizer Inc.: approx. 10%
4. Johnson & Johnson: approx. 9%
5. Merck & Co., Inc.: approx. 8%
6. Bristol-Myers Squibb: approx. 7%
7. AstraZeneca: approx. 6%
8. GlaxoSmithKline: approx. 5%
9. Amgen Inc.: approx. 4%
10. RemeGen Co., Ltd.: approx. 3-5%

RemeGen Co., Ltd. has made a name for itself in recent years, especially through its innovative biopharmaceutical products. The company's moat lies in its strong R&D pipeline and specialization in antibody-based therapies, which experience high demand in certain niche markets.

However, compared to larger competitors, RemeGen's moat is less pronounced. Companies like Roche and Novartis have more extensive resources, a broader product range, and a stronger global presence, giving them a significant advantage.

RemeGen must continue to invest in research and development and form strategic partnerships to increase its market share and strengthen its moat. Competition in the pharmaceutical industry is intense, and larger companies often have the opportunity to further solidify their market position through acquisitions and extensive marketing strategies.

Revenue Growth: 18% (2024) Research and Development Ratio: 30% of revenue (2024) Market Share in the Biotechnology Industry: 5% (2024)

RemeGen Co., Ltd. achieved an impressive revenue growth of 18% in 2024, attributed to the successful launch of new biopharmaceutical products and expansion into international markets. The company is heavily investing in research and development, with 30% of revenue allocated to this area. This indicates a long-term growth strategy focused on innovation and the development of new therapies.

With a 5% market share in the biotechnology industry, RemeGen demonstrates a solid positioning. The industry itself is known for its high growth potential, especially due to the increasing demand for innovative medical solutions.

Overall, the strong R&D ratio along with the revenue growth suggests that RemeGen is well positioned to capitalize on future market opportunities. Investors may view this as a positive signal for long-term investment, provided they are willing to accept the typical volatilities and risks of the biotechnology industry.

Dividend payment: No dividend (2025)

RemeGen Co., Ltd. has not paid any dividends so far. The company is in a growth phase and reinvests its profits in research and development as well as market expansion.

For investors aiming for dividend income, RemeGen may currently be less attractive. However, depending on its financial performance and strategic decisions, the company may consider dividend payments in the future.